An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Mycosis Fungoides
Interventions
DRUG

0.04% Mechlorethamine gel

Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.

Trial Locations (11)

10016

Columbia University, Dept of Dermatology, New York

NYU Medical Center Dept. of Dermatology, New York

27710

Duke University Medical Center, Durham

53791

University of Wisconsin, Madison

61611

Northwestern University-Dept. of Dermatology, Chicago

74104

Oklahoma University, Tulsa

75390

University of Texas, Southwestern Medical Center, Dallas

77030

The University of Texas, M.D. Anderson Cancer Center, Houston

84107

Utah Clinical Trials, LLC, Salt Lake City

94305

Stanford University Medical Center, Stanford

19111-2497

Fox Chase Cancer Center, Philadelphia

Sponsors
All Listed Sponsors
lead

Yaupon Therapeutics

INDUSTRY

NCT00535470 - An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | Biotech Hunter | Biotech Hunter